The mitochondrial enzyme, amyloid binding alcohol dehydrogenase (ABAD), has been shown to mediate the cytotoxic effects of Amyloid-β within the Alzheimer's diseased brain. Mutational studies have shown that ABAD must be catalytically active for cytotoxicity to be observed and therefore the direct inhibition of ABAD may offer a novel therapeutic strategy to treat the disease. In 2006, Xie et al. identified benzothiazole urea analogues capable of perturbing the ABAD-Aβ interaction. We hypothesised that the capability of these analogues to disrupt the interaction may infer the ability to bind to ABAD, which in turn may inhibit ABAD activity. We have subsequently generated many series of benzothiazole urea derivatives and assessed their ability to inhibit ABAD; identifying and characterising several potent inhibitors (articles in review) and we have now made several bioisostere modifications, aiming for elevated potency and more desirable pharmacokinetic properties, currently under investigation. Another aspect of our screening strategy has been to devise a high throughput screening (HTS) assay from our in house enzyme activity assay. This has allowed us to screen larger libraries (6000 pilot screen) and produced compounds which are already (or have been previously) FDA approved and could be repurposed, as well as small molecule compounds which are advantageous in drug screening and fit many of the chemical characteristics often seen in drug like molecules. Excitingly our HTS assay was also accepted into a lucrative pharmaceutical industry backed program that produced a validated hit list of molecules as another aspect of our research. To assess the compounds therapeutic potential we are using many different techniques, but our primary screening strategy utilises recombinant ABAD enzyme extract to measure ABAD activity, followed by cell based and biophysical deselection assays to verify the inhibitory nature, the cell permeability and cytotoxicity of these compounds.
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